Elanco Animal Health (NYSE:ELAN) Given New $30.00 Price Target at KeyCorp

Elanco Animal Health (NYSE:ELAN) had its price objective hoisted by KeyCorp from $29.00 to $30.00 in a report released on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the stock. KeyCorp’s target price would suggest a potential upside of 24.49% from the stock’s previous close.

A number of other equities research analysts have also recently commented on ELAN. Piper Sandler reiterated an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. TD Cowen increased their price objective on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Weiss Ratings upgraded shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, July 31st. Citigroup lifted their price target on Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Finally, Morgan Stanley boosted their price target on Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $28.82.

Elanco Animal Health Stock Down 8.1%

Elanco Animal Health stock traded down $2.12 during midday trading on Thursday, hitting $24.10. 5,500,356 shares of the company’s stock were exchanged, compared to its average volume of 5,381,625. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16. The company has a market cap of $12.04 billion, a PE ratio of -48.38, a P/E/G ratio of 1.67 and a beta of 1.67. The firm has a 50-day moving average of $24.73 and a two-hundred day moving average of $24.10. Elanco Animal Health has a 12 month low of $15.50 and a 12 month high of $27.98.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.07. The business had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.31 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The business’s revenue was up 10.2% compared to the same quarter last year. During the same period last year, the business posted $0.26 EPS. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, analysts expect that Elanco Animal Health will post 1.11 earnings per share for the current fiscal year.

Insider Activity at Elanco Animal Health

In other news, insider Rajeev A. Modi bought 4,911 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The stock was purchased at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the purchase, the insider directly owned 160,812 shares in the company, valued at approximately $3,272,524.20. This trade represents a 3.15% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jeffrey N. Simmons purchased 4,971 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were purchased at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the transaction, the chief executive officer owned 171,971 shares of the company’s stock, valued at $3,454,897.39. This trade represents a 2.98% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 1.14% of the stock is owned by insiders.

Institutional Trading of Elanco Animal Health

Institutional investors and hedge funds have recently modified their holdings of the stock. Parallel Advisors LLC increased its position in Elanco Animal Health by 5.9% during the fourth quarter. Parallel Advisors LLC now owns 7,060 shares of the company’s stock worth $160,000 after buying an additional 392 shares during the period. Sapient Capital LLC boosted its holdings in shares of Elanco Animal Health by 0.3% in the second quarter. Sapient Capital LLC now owns 128,573 shares of the company’s stock valued at $3,164,000 after acquiring an additional 420 shares during the period. Lazard Asset Management LLC grew its position in shares of Elanco Animal Health by 0.6% during the fourth quarter. Lazard Asset Management LLC now owns 72,065 shares of the company’s stock worth $1,631,000 after acquiring an additional 425 shares during the last quarter. Northwestern Mutual Investment Management Company LLC increased its holdings in shares of Elanco Animal Health by 0.4% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 111,166 shares of the company’s stock valued at $2,516,000 after acquiring an additional 428 shares during the period. Finally, Meeder Advisory Services Inc. raised its position in Elanco Animal Health by 4.8% in the 4th quarter. Meeder Advisory Services Inc. now owns 11,235 shares of the company’s stock valued at $254,000 after purchasing an additional 510 shares during the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Trending Headlines about Elanco Animal Health

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Second-quarter results exceeded expectations: Revenue increased 10% year over year to $1.368 billion, ahead of the $1.31 billion consensus estimate. Adjusted EPS was $0.34 versus expectations of $0.27 and $0.26 in the year-ago quarter. Organic constant-currency growth was 8%. Elanco Animal Health Reports Second Quarter 2026 Results
• Positive Sentiment: Full-year guidance was raised: Elanco now expects 2026 revenue of $5.09 billion to $5.14 billion, adjusted EBITDA of $1.01 billion to $1.035 billion, and adjusted EPS of $1.10 to $1.16. The EPS range is above the $1.07 analyst consensus, with midpoint adjusted EPS growth of approximately 20% year over year. Elanco Lifts Outlook as 2Q Profit, Revenue Rise
• Positive Sentiment: Innovation products are gaining traction: Management raised its 2026 innovation-revenue target to $1.25 billion, while Zenrelia reached “blockbuster” status. This supports expectations for continued growth from newer products.
• Positive Sentiment: Balance-sheet targets improved: Elanco expects its year-end net leverage ratio to decline to approximately 3.0 times adjusted EBITDA, compared with 3.1 times at the end of the quarter.
• Neutral Sentiment: Third-quarter guidance was broadly in line with estimates: Adjusted EPS is projected at $0.19 to $0.22 and revenue at approximately $1.2 billion, limiting the immediate upside from the near-term forecast.
• Negative Sentiment: Reported profitability remains pressured: GAAP net income was $54 million, or $0.11 per share, and the company continued to report a negative net margin, highlighting the gap between adjusted and reported earnings.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.